<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02103439</url>
  </required_header>
  <id_info>
    <org_study_id>BCD-016-4</org_study_id>
    <nct_id>NCT02103439</nct_id>
  </id_info>
  <brief_title>An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients</brief_title>
  <official_title>Multicenter Open-label Randomized, Comparative Clinical Study to Evaluate Efficacy and Safety of Algeron (Cepeginterferon Alfa-2b, CJSC &quot;BIOCAD&quot;, Russia) With Ribavirin Compared to PegIntron (Peginterferon Alfa-2b, Schering-Plough Labo N.V., Belgium) With Ribavirin in Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocad</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biocad</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to demonstrate the noninferiority of Algeron in combination with
      ribavirin compared to PegIntron in combination with ribavirin in treatment of chronic
      hepatitis C in Human Immunodeficiency Virus-1 infected patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The course of treatment in both groups shall be 12 weeks, and efficacy analysis, i.e. rate of
      rapid (after the 4th week) and early (after the 12th week) virologic response will be based
      on polymerase chain reaction data. For patients with treatment failure after the 12th week
      the antiviral therapy shall be discontinued. All patients who require further anti-viral
      treatment will receive a combination treatment with Algeron / PegIntron and ribavirin for
      another 36 weeks. Sustained virologic response will be assessed 24 weeks after last dose of
      study treatment.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Early Virological Response</measure>
    <time_frame>12 weeks</time_frame>
    <description>Proportion of randomized patients achieving early virologic response - negative polymerase chain reaction result for Hepatitis C Virus ribonucleic acid (&lt; 15 IU/ml) or ≥ 2log10 decrease of viral load after 12 weeks of study treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Early Virological Response in Patients With Different Hepatitis C Virus Genotypes</measure>
    <time_frame>12 weeks</time_frame>
    <description>Proportion of randomized patients with different Hepatitis C Virus (HCV) genotypes achieving early virologic response - negative polymerase chain reaction result for HCV ribonucleic acid (&lt; 15 IU/ml) or ≥ 2log10 decrease of viral load after 12 weeks of study treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rapid Virological Response</measure>
    <time_frame>4 weeks</time_frame>
    <description>Proportion of randomized patients achieving rapid virologic response - negative polymerase chain reaction result for Hepatitis C Virus ribonucleic acid (&lt; 15 IU/ml) after 4 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rapid Virological Response in Patients With Different Hepatitis C Virus Genotypes</measure>
    <time_frame>4 weeks</time_frame>
    <description>Proportion of randomized patients with different Hepatitis C Virus (HCV) genotypes achieving rapid virological response - negative polymerase chain reaction result for HCV ribonucleic acid (&lt; 15 IU/ml) after 4 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral Breakthrough</measure>
    <time_frame>screening data and at 4 or 12 weeks of treatment.</time_frame>
    <description>Proportion of patients in each groups with level of Hepatitis C Virus ribonucleic acid &gt; 15 IU/ml after Hepatitis C Virus ribonucleic acid was not present or Hepatitis C Virus ribonucleic acid was increased by more than 1log10 from baseline at 4 or 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical Response</measure>
    <time_frame>12 weeks</time_frame>
    <description>Proportion of patients in each group with alanine aminotransferase level ≤ upper normal limit after 12 weeks of therapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Hepatitis</condition>
  <condition>Hepatitis C</condition>
  <condition>Hepatitis C/ Human Immunodeficiency Virus Coinfection</condition>
  <arm_group>
    <arm_group_label>Algeron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Algeron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight &lt;65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight &gt; 105 kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PegIntron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PegIntron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight &lt;65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight &gt; 105 kg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Algeron</intervention_name>
    <description>1.5 µg/kg of body weight subcutaneously, once a week</description>
    <arm_group_label>Algeron</arm_group_label>
    <other_name>Cepeginterferon alfa-2b</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PegIntron</intervention_name>
    <description>1.5 µg/kg of body weight subcutaneously, once a week</description>
    <arm_group_label>PegIntron</arm_group_label>
    <other_name>peginterferon alfa-2b</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed Informed Consent Form.

          -  Chronic hepatitis C (genotypes 1а, 1b, 2, 3, 4) confirmed by positive result of
             hepatitis C virus ribonucleic acid during &gt; 6 months before screening visit or
             accompanied with increase in alanine aminotransferase (ALT) level &gt; 6 months before
             screening visit.

          -  Confirmed Human Immunodeficiency Virus-1 infection based on enzyme-linked
             immunosorbent assay and immune blotting results.

          -  Clinically sustained phase of Human Immunodeficiency Virus-1 infection with absence of
             active opportunistic Human Immunodeficiency Virus-associated diseases for at least 30
             calendar days before inclusion in the study.

          -  Level of CD4+-lymphocytes is not less than 500 cells/mm3 for patients not requiring
             highly active antiretroviral therapy and which will not be assigned to antiretroviral
             therapy during the study period.

          -  For patients receiving sustained highly active antiretroviral therapy for not less
             than 12 weeks and planning to continue comply with this treatment regimen during the
             following 24 weeks, level of CD4+-lymphocytes ≥300 cells/mm3, Human Immunodeficiency
             Virus ribonucleic acid ≤50 copies/ml.

          -  Men and women aged 18 to 70 inclusively.

          -  Body mass index in the range of 18 - 30 kg/m2 inclusively .

          -  Preserved protein-synthetizing liver function (International Normalized Ratio &lt; 1.7,
             albumin &gt; 35 g/l).

          -  Absence of signs of hepatic encephalopathy and ascites according to clinical
             examination and ultrasound examination.

          -  Patients with preserved child-bearing potential and their partners agree to use
             barrier method of contraception during the whole period of therapy and during 7 months
             after the treatment completion.

          -  Documentary confirmed results of liver elastography (fibroscan) during last year
             before enrollment in the study or patient agreement to undergo this examination during
             screening.

        Exclusion Criteria:

          -  Intolerance of alfa-interferons, ribavirin or any components of tested drug product
             based on medical history.

          -  Presence of hepatitis B, A, E markers.

          -  Presence of documentary confirmed clinically significant concurrent liver diseases
             (alcoholic liver cirrhosis, drug-induced liver cirrhosis, autoimmune hepatitis,
             hemochromatosis, Wilson's disease, non-alcoholic steatohepatitis, biliary cirrhosis
             etc.).

          -  Past history of Hepatitis C Virus treatment with interferon alfa or pegylated
             interferon alfa.

          -  For patients receiving sustained highly active antiretroviral therapy - presence of
             nevirapine, stavudine, zidovudine, didanosine in treatment regimen.

          -  Use of injectable and non-injectable interferons alfa/ interferon inducers for any
             indication (except for hepatitis C), radiotherapy, cytotoxic chemotherapy for one
             month prior to inclusion in the study.

          -  Cholestic hepatitis (level of direct bilirubin, alkaline phosphatase, gamma
             glutamyltransferase, exceeding upper normal limit in &gt; 5 times).

          -  Decompensated liver cirrhosis confirmed with results of laboratory analyses
             (Child-Pugh class B, C) or ultrasound examination.

          -  Any documentary confirmed autoimmune diseases (such as Crohn's disease, ulcerative
             colitis, systemic lupus erythematosus, idiopathic thrombocytopenic purpura,
             scleroderma, autoimmune hemolytic anemia, severe psoriasis).

          -  Deviations of hematologic (hemoglobin less than lower normal limit; neutrophils &lt; 1.5
             x 10^9/l; thrombocytes &lt; 90 x 10^9/ l) and biochemical (creatinine level &gt; 1.5 times
             higher upper normal limit, ALT is &gt; 10 times higher upper normal limit) parameters.

          -  Documentary confirmed diagnosis of hemoglobinopathy (for example, thalassemia,
             sickle-cell anemia).

          -  Severe depression, schizophrenia, any other mental disorders which according to the
             investigator are contraindications for antiviral treatment.

          -  Epilepsy and/or central nervous system disorder.

          -  Disorder of thyroid function (level of thyroid stimulating hormone out of the normal
             range).

          -  Documentary confirmed or suspected hepatocellular carcinoma based on the results of
             alfa-fetoprotein (AFP) assay ≥ upper normal limit.

          -  Antinuclear antibodies (ANA) titer measured at screening is not less than 1:640 or
             documentary confirmed signs of autoimmune hepatitis based on the results of biopsy.

          -  Documentary confirmed malignant neoplasms.

          -  Documentary confirmed lung diseases associated with respiratory failure.

          -  Treatment of Human Immunodeficiency Virus-1 with immunotherapeutic vaccines within 90
             days prior to screening.

          -  Necessity in assignment of antimycobacterial therapy.

          -  Pregnancy, lactation period.

          -  Documentary confirmed retinopathy (for example, cytomegalovirus retinitis, macular
             degeneration).

          -  Severe concurrent diseases (for example, severe arterial hypertension, sever coronary
             heart disease, heart failure, decompensated diabetes mellitus and other) which are
             contraindications for antiviral therapy according to the investigator opinion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory Moshkovich, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Institution of Nizhny Novgorod region &quot;Regional Center for Prevention and Control of AIDS and other infectious diseases&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Firaya Nagimova, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Public Healthcare Institution National Center for the Prevention and Control of AIDS and other infectious diseases of the Ministry of Health of the Republic of Tatarstan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Oleg Kozyrev, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Healthcare Institution &quot;Volgograd Regional Center for the Prevention and Control of AIDS and infectious diseases&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrey Shuldyakov, M.D., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Budgetary Higher Vocational Education Institution V.I. Razumovsky Saratov State University of medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vadim Rassokhin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Healthcare Institution Center for the Prevention and Control of AIDS and infectious diseases of the city, St.Petersburg CityHealth Department</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lidia Sklar, M.D., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Budgetary Higher Vocational Education Institution Pacific State Medical University, Ministry of Health of the Russian Federation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>State Public Healthcare Institution National Center for the Prevention and Control of AIDS and other infectious diseases of the Ministry of Health of the Republic of Tatarstan</name>
      <address>
        <city>Kazan</city>
        <state>Republic of Tatarstan</state>
        <zip>420097</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Institution of Nizhny Novgorod region &quot;Regional Center for Prevention and Control of AIDS and other infectious diseases&quot;</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution Center for the Prevention and Control of AIDS and infectious diseases of the city, St.Petersburg CityHealth Department</name>
      <address>
        <city>Sankt-Petersburg</city>
        <zip>190103</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Higher Vocational Education Institution V.I. Razumovsky Saratov State University of medicine</name>
      <address>
        <city>Saratov</city>
        <zip>410012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Higher Vocational Education Institution Pacific State Medical University, Ministry of Health of the Russian Federation</name>
      <address>
        <city>Vladivostok</city>
        <zip>690002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution &quot;Volgograd Regional Center for the Prevention and Control of AIDS and infectious diseases&quot;</name>
      <address>
        <city>Volgograd</city>
        <zip>400040</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2014</study_first_submitted>
  <study_first_submitted_qc>April 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2014</study_first_posted>
  <results_first_submitted>May 21, 2015</results_first_submitted>
  <results_first_submitted_qc>July 17, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 21, 2015</results_first_posted>
  <last_update_submitted>January 12, 2016</last_update_submitted>
  <last_update_submitted_qc>January 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <keyword>Cepeginterferon alfa</keyword>
  <keyword>Peginterferon</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Coinfection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Algeron</title>
          <description>Algeron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight &lt;65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight &gt; 105 kg)
Algeron: 1.5 µg/kg of body weight subcutaneously, once a week</description>
        </group>
        <group group_id="P2">
          <title>PegIntron</title>
          <description>PegIntron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight &lt;65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight &gt; 105 kg).
PegIntron: 1.5 µg/kg of body weight subcutaneously, once a week</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Algeron</title>
          <description>Algeron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight &lt;65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight &gt; 105 kg)
Algeron: 1.5 µg/kg of body weight subcutaneously, once a week</description>
        </group>
        <group group_id="B2">
          <title>PegIntron</title>
          <description>PegIntron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight &lt;65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight &gt; 105 kg).
PegIntron: 1.5 µg/kg of body weight subcutaneously, once a week</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="70"/>
            <count group_id="B2" value="70"/>
            <count group_id="B3" value="140"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" lower_limit="30" upper_limit="37"/>
                    <measurement group_id="B2" value="34" lower_limit="31" upper_limit="37"/>
                    <measurement group_id="B3" value="33.5" lower_limit="31" upper_limit="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Early Virological Response</title>
        <description>Proportion of randomized patients achieving early virologic response - negative polymerase chain reaction result for Hepatitis C Virus ribonucleic acid (&lt; 15 IU/ml) or ≥ 2log10 decrease of viral load after 12 weeks of study treatment</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Algeron</title>
            <description>Algeron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight &lt;65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight &gt; 105 kg)
Algeron: 1.5 µg/kg of body weight subcutaneously, once a week</description>
          </group>
          <group group_id="O2">
            <title>PegIntron</title>
            <description>PegIntron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight &lt;65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight &gt; 105 kg).
PegIntron: 1.5 µg/kg of body weight subcutaneously, once a week</description>
          </group>
        </group_list>
        <measure>
          <title>Early Virological Response</title>
          <description>Proportion of randomized patients achieving early virologic response - negative polymerase chain reaction result for Hepatitis C Virus ribonucleic acid (&lt; 15 IU/ml) or ≥ 2log10 decrease of viral load after 12 weeks of study treatment</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0"/>
                    <measurement group_id="O2" value="81.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>the lower limit of the 95% confidence interval for the difference in proportions between the difference in the early virological response rate with Algeron and PegIntron should be higher than the non-inferiority margin of 0.2 (-20%)</non_inferiority_desc>
            <p_value>0.227</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rapid Virological Response</title>
        <description>Proportion of randomized patients achieving rapid virologic response - negative polymerase chain reaction result for Hepatitis C Virus ribonucleic acid (&lt; 15 IU/ml) after 4 weeks of treatment</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Algeron</title>
            <description>Algeron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight &lt;65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight &gt; 105 kg)
Algeron: 1.5 µg/kg of body weight subcutaneously, once a week</description>
          </group>
          <group group_id="O2">
            <title>PegIntron</title>
            <description>PegIntron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight &lt;65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight &gt; 105 kg).
PegIntron: 1.5 µg/kg of body weight subcutaneously, once a week</description>
          </group>
        </group_list>
        <measure>
          <title>Rapid Virological Response</title>
          <description>Proportion of randomized patients achieving rapid virologic response - negative polymerase chain reaction result for Hepatitis C Virus ribonucleic acid (&lt; 15 IU/ml) after 4 weeks of treatment</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.4"/>
                    <measurement group_id="O2" value="37.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>the lower limit of the 95 % confidence interval between the difference in rate of rapid virological response with Algeron and PegIntron should be more than the non-inferiority margin (-20 %)</non_inferiority_desc>
            <p_value>&gt; 0.05</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rapid Virological Response in Patients With Different Hepatitis C Virus Genotypes</title>
        <description>Proportion of randomized patients with different Hepatitis C Virus (HCV) genotypes achieving rapid virological response - negative polymerase chain reaction result for HCV ribonucleic acid (&lt; 15 IU/ml) after 4 weeks of treatment</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Algeron - HCV-1</title>
            <description>Patients with HCV genotype 1, received Algeron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight &lt;65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight &gt; 105 kg)
Algeron: 1.5 µg/kg of body weight subcutaneously, once a week</description>
          </group>
          <group group_id="O2">
            <title>Algeron - HCV-2/3</title>
            <description>Patients with HCV genotype 2 or 3, received Algeron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight &lt;65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight &gt; 105 kg)
Algeron: 1.5 µg/kg of body weight subcutaneously, once a week</description>
          </group>
          <group group_id="O3">
            <title>PegIntron - HCV-1</title>
            <description>Patients with HCV genotype 1, received PegIntron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight &lt;65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight &gt; 105 kg).
PegIntron: 1.5 µg/kg of body weight subcutaneously, once a week</description>
          </group>
          <group group_id="O4">
            <title>PegIntron - HCV-2/3</title>
            <description>Patients with HCV genotype 2 or 3, received PegIntron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight &lt;65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight &gt; 105 kg).
PegIntron: 1.5 µg/kg of body weight subcutaneously, once a week</description>
          </group>
        </group_list>
        <measure>
          <title>Rapid Virological Response in Patients With Different Hepatitis C Virus Genotypes</title>
          <description>Proportion of randomized patients with different Hepatitis C Virus (HCV) genotypes achieving rapid virological response - negative polymerase chain reaction result for HCV ribonucleic acid (&lt; 15 IU/ml) after 4 weeks of treatment</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.5"/>
                    <measurement group_id="O2" value="77.8"/>
                    <measurement group_id="O3" value="21.2"/>
                    <measurement group_id="O4" value="51.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Viral Breakthrough</title>
        <description>Proportion of patients in each groups with level of Hepatitis C Virus ribonucleic acid &gt; 15 IU/ml after Hepatitis C Virus ribonucleic acid was not present or Hepatitis C Virus ribonucleic acid was increased by more than 1log10 from baseline at 4 or 12 weeks of treatment</description>
        <time_frame>screening data and at 4 or 12 weeks of treatment.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Algeron</title>
            <description>Algeron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight &lt;65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight &gt; 105 kg)
Algeron: 1.5 µg/kg of body weight subcutaneously, once a week</description>
          </group>
          <group group_id="O2">
            <title>PegIntron</title>
            <description>PegIntron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight &lt;65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight &gt; 105 kg).
PegIntron: 1.5 µg/kg of body weight subcutaneously, once a week</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Breakthrough</title>
          <description>Proportion of patients in each groups with level of Hepatitis C Virus ribonucleic acid &gt; 15 IU/ml after Hepatitis C Virus ribonucleic acid was not present or Hepatitis C Virus ribonucleic acid was increased by more than 1log10 from baseline at 4 or 12 weeks of treatment</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Early Virological Response in Patients With Different Hepatitis C Virus Genotypes</title>
        <description>Proportion of randomized patients with different Hepatitis C Virus (HCV) genotypes achieving early virologic response - negative polymerase chain reaction result for HCV ribonucleic acid (&lt; 15 IU/ml) or ≥ 2log10 decrease of viral load after 12 weeks of study treatment</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Algeron - HCV-1</title>
            <description>Patients with HCV genotype 1, received Algeron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight &lt;65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight &gt; 105 kg)
Algeron: 1.5 µg/kg of body weight subcutaneously, once a week</description>
          </group>
          <group group_id="O2">
            <title>Algeron - HCV-2/3</title>
            <description>Patients with HCV genotype 2 or 3, received Algeron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight &lt;65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight &gt; 105 kg)
Algeron: 1.5 µg/kg of body weight subcutaneously, once a week</description>
          </group>
          <group group_id="O3">
            <title>PegIntron - HCV-1</title>
            <description>Patients with HCV genotype 1, received PegIntron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight &lt;65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight &gt; 105 kg).
PegIntron: 1.5 µg/kg of body weight subcutaneously, once a week</description>
          </group>
          <group group_id="O4">
            <title>PegIntron - HCV-2/3</title>
            <description>Patients with HCV genotype 2 or 3, received PegIntron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight &lt;65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight &gt; 105 kg).
PegIntron: 1.5 µg/kg of body weight subcutaneously, once a week</description>
          </group>
        </group_list>
        <measure>
          <title>Early Virological Response in Patients With Different Hepatitis C Virus Genotypes</title>
          <description>Proportion of randomized patients with different Hepatitis C Virus (HCV) genotypes achieving early virologic response - negative polymerase chain reaction result for HCV ribonucleic acid (&lt; 15 IU/ml) or ≥ 2log10 decrease of viral load after 12 weeks of study treatment</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.4"/>
                    <measurement group_id="O2" value="97.2"/>
                    <measurement group_id="O3" value="75.8"/>
                    <measurement group_id="O4" value="88.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biochemical Response</title>
        <description>Proportion of patients in each group with alanine aminotransferase level ≤ upper normal limit after 12 weeks of therapy</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Algeron</title>
            <description>Algeron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight &lt;65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight &gt; 105 kg)
Algeron: 1.5 µg/kg of body weight subcutaneously, once a week</description>
          </group>
          <group group_id="O2">
            <title>PegIntron</title>
            <description>PegIntron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight &lt;65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight &gt; 105 kg).
PegIntron: 1.5 µg/kg of body weight subcutaneously, once a week</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemical Response</title>
          <description>Proportion of patients in each group with alanine aminotransferase level ≤ upper normal limit after 12 weeks of therapy</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.6"/>
                    <measurement group_id="O2" value="82.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <desc>The number of patients for the efficacy analysis was 140 patients. 141 patients were included in the safety analysis, including 1 patient in PegIntron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria [previous AVT cycle], who was not considered to be enrolled in the study due to serious protocol violation.</desc>
      <group_list>
        <group group_id="E1">
          <title>Algeron</title>
          <description>Algeron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight &lt;65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight &gt; 105 kg)
Algeron: 1.5 µg/kg of body weight subcutaneously, once a week</description>
        </group>
        <group group_id="E2">
          <title>PegIntron</title>
          <description>PegIntron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight &lt;65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight &gt; 105 kg).
PegIntron: 1.5 µg/kg of body weight subcutaneously, once a week
The safety analysis included 71 patients received at least 1 dose of PegIntron (taking into account one patient withdrawn at early stages of the study due to a protocol violation [previous treatment of hepatitis C with interferon alfa], who was withdrawn from the mITT-analysis)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>CTCAE 4.03 Grade 4 anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cavitary pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leucopenia</sub_title>
                <counts group_id="E1" events="67" subjects_affected="60" subjects_at_risk="70"/>
                <counts group_id="E2" events="69" subjects_affected="59" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="67" subjects_affected="53" subjects_at_risk="70"/>
                <counts group_id="E2" events="66" subjects_affected="51" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="52" subjects_affected="43" subjects_at_risk="70"/>
                <counts group_id="E2" events="62" subjects_affected="55" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Decreased level of CD4+ lymphocytes</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="70"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="39" subjects_affected="39" subjects_at_risk="70"/>
                <counts group_id="E2" events="37" subjects_affected="36" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Need in filgrastim</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="50" subjects_affected="49" subjects_at_risk="70"/>
                <counts group_id="E2" events="59" subjects_affected="57" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Need in Rebetol dose correction due to anemia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="70"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="70"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="70"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Increased thyroid stimulating hormone</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="21" subjects_affected="7" subjects_at_risk="70"/>
                <counts group_id="E2" events="8" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="70"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Flu-like syndrome</sub_title>
                <counts group_id="E1" events="46" subjects_affected="38" subjects_at_risk="70"/>
                <counts group_id="E2" events="87" subjects_affected="41" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Asthenia (weakness, fatigue)</sub_title>
                <counts group_id="E1" events="25" subjects_affected="17" subjects_at_risk="70"/>
                <counts group_id="E2" events="23" subjects_affected="16" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="27" subjects_affected="22" subjects_at_risk="70"/>
                <counts group_id="E2" events="28" subjects_affected="26" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Direct bilirubin increased</sub_title>
                <counts group_id="E1" events="33" subjects_affected="31" subjects_at_risk="70"/>
                <counts group_id="E2" events="34" subjects_affected="31" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Increased albumin</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="70"/>
                <counts group_id="E2" events="29" subjects_affected="25" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Increased alanine aminotranferase</sub_title>
                <counts group_id="E1" events="26" subjects_affected="25" subjects_at_risk="70"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Increased aspartate aminotranferase</sub_title>
                <counts group_id="E1" events="32" subjects_affected="28" subjects_at_risk="70"/>
                <counts group_id="E2" events="31" subjects_affected="29" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Increased gamma glumamyltransferase</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="70"/>
                <counts group_id="E2" events="36" subjects_affected="31" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Increased alkaline phosphotase</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="70"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Increased triglycerides</sub_title>
                <counts group_id="E1" events="38" subjects_affected="34" subjects_at_risk="70"/>
                <counts group_id="E2" events="42" subjects_affected="37" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Increased cholesterol</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="70"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="70"/>
                <counts group_id="E2" events="18" subjects_affected="6" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" events="10" subjects_affected="6" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="16" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="38" subjects_affected="12" subjects_at_risk="70"/>
                <counts group_id="E2" events="25" subjects_affected="13" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Sleep disorders</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability, emotional lability</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Increased creatinine</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="70"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin itch</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Skin redness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Skin dryness and exfoliation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hyperemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Yulia Linkova Medical Director</name_or_title>
      <organization>Biocad</organization>
      <phone>+7 (495) 992 66 28 ext 930</phone>
      <email>linkova@biocad.ru</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

